Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03473301 · ClinicalTrials.gov registry record · Phase 1

A Study of UCB and MSCs in Children With CP: ACCeNT-CP

A Phase 1 study, sponsored by Joanne Kurtzberg, MD.

Completed
Registry status
Phase 1
Development phase
91
Enrollment target

NCT03473301 is a Phase 1 study that has completed, run by Joanne Kurtzberg, MD. The registered enrollment target is 91 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03473301, a Phase 1 study, has completed, sponsored by Joanne Kurtzberg, MD.

COMPLETED
Registry status
Phase 1
Development phase
91 participants
Enrollment target

Study Summary

The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy. In addition, this study will contribute much needed data to the clinical trials community on the natural history of the motor function in CP over short-term (less than 1 year) time periods relevant to the conduct of clinical trials and assess the safety of AlloCB and hCT-MSC infusion in children with cerebral palsy.

Interventions

  • BIOLOGICAL Infusion of allogeneic umbilical cord blood
  • BIOLOGICAL Infusion of MSCs

Trial Details

FieldValue
Enrollment Target 91 participants
Start Date 2018-04-10
Est. Completion 2021-05-31
Phase Phase 1

Sponsor

Joanne Kurtzberg, MD

15 total trials

What the Registry Record Tells You About NCT03473301

The ClinicalTrials.gov registry entry for NCT03473301 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Joanne Kurtzberg, MD, which has 15 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which Infusion of allogeneic umbilical cord blood is the first listed.

NCT03473301 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03473301 about?

NCT03473301 is a clinical study titled "A Study of UCB and MSCs in Children With CP: ACCeNT-CP". The main purpose of this study is to estimate change in motor function 12 months after treatment with a single dose of allogeneic umbilical cord blood (AlloCB) or repeated doses of umbilical cord tissue-derived mesenchymal stromal cells (hCT-MSC) in children with cerebral palsy. In addition, this st...

What is the current status of trial NCT03473301?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 91 participants. The study started on 2018-04-10. Estimated completion is 2021-05-31.

What interventions are being tested in trial NCT03473301?

The interventions under investigation include: Infusion of allogeneic umbilical cord blood (BIOLOGICAL), Infusion of MSCs (BIOLOGICAL).

Who is sponsoring clinical trial NCT03473301?

This trial is sponsored by Joanne Kurtzberg, MD, which has 15 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.